Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C37H45Cl2N2O2.C6H5O3S |
Molecular Weight | 777.839 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-]S(=O)(=O)C1=CC=CC=C1.CC(C)OC2=CC(CC(=O)N3CCC[C@@](CC[N+]45CCC(CC4)(CC5)C6=CC=CC=C6)(C3)C7=CC=C(Cl)C(Cl)=C7)=CC=C2
InChI
InChIKey=PQRLQZNKDQQMBC-LSYPWIJNSA-M
InChI=1S/C37H45Cl2N2O2.C6H6O3S/c1-28(2)43-32-11-6-8-29(24-32)25-35(42)40-19-7-14-37(27-40,31-12-13-33(38)34(39)26-31)18-23-41-20-15-36(16-21-41,17-22-41)30-9-4-3-5-10-30;7-10(8,9)6-4-2-1-3-5-6/h3-6,8-13,24,26,28H,7,14-23,25,27H2,1-2H3;1-5H,(H,7,8,9)/q+1;/p-1/t36?,37-,41?;/m1./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/7509286Curator's Comment: the description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9824398 | https://www.ncbi.nlm.nih.gov/pubmed/9873386 | https://www.ncbi.nlm.nih.gov/pubmed/9243595 | https://www.ncbi.nlm.nih.gov/pubmed/20497542
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7509286
Curator's Comment: the description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9824398 | https://www.ncbi.nlm.nih.gov/pubmed/9873386 | https://www.ncbi.nlm.nih.gov/pubmed/9243595 | https://www.ncbi.nlm.nih.gov/pubmed/20497542
Nolpitantium (SR-140333) is a highly selective nonpeptide antagonist of neurokinin-1 (NK1) receptor. Nolpitantium potently, selectively and competitively inhibited substance P binding to NK1 receptors from various animal species, including humans. In vitro, it was a potent antagonist in functional assays for NK1 receptors such as [Sar9, Met(O2)11]substance P-induced endothelium-dependent relaxation of rabbit pulmonary artery and contraction of guinea-pig ileum. Up to 1 mkM, Nolpitantium had no effect in bioassays for NK2 and NK3 receptors. The antagonism exerted by Nolpitantium toward NK1 receptors was apparently non-competitive, with pD2' values between 9.65 and 10.16 in the different assays. Nolpitantium also blocked in vitro [Sar9, Met(O2)11]substance P-induced release of acetylcholine from rat striatum. In vivo, Nolpitantium exerted highly potent antagonism toward [Sar9, Met(O2)11]substance P-induced hypotension in dogs, bronchoconstriction in guinea-pig) and plasma extravasation in rats. Nolpitantium was found to be effective in the modulation of the inflammatory response and airway remodeling in mice. Nolpitantium is reported to cause antagonism of the SP-induced relaxations of human isolated intralobar pulmonary arterial rings. Nolpitantium also blocked the activation of rat thalamic neurons after nociceptive stimulation. Nolpitantium has been shown to reduce the severity of inflammation in trinitrobenzene sulfonic acid-induced colitis in the rat colon. Nolpitantium inhibited mustard oil-induced plasma protein extravasations in the dorsal skin of the rat hind paw. Nolpitantium had been in some phase II clinical trials but further studies were discontinued.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL249 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9873386 |
0.019 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. | 1996 Aug 23 |
|
Ava[L-Pro9,N-MeLeu10] substance P(7-11) (GR 73632) and Sar9, Met(O2)11 increase distention-induced peristalsis through activation of neurokinin-1 receptors on smooth muscle and interstitial cells of cajal. | 2006 Apr |
|
Expression and function of human hemokinin-1 in human and guinea pig airways. | 2010 Oct 7 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00232258
Single daily doses of 600 mg SR140333B or 1800 mg of SR140333B for eight weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20497542
The human breast cancer cell line T47D was used for activity evaluation. Nolpitantium were dissolved in culture medium respectively to obtain experimental concentration (ranging from 10^-9M to 10^-5M). Cell proliferation was assessed using MTT assay. Cells were cultured in 96-well plates and the cell numbers were quantified using a coulter counter (Coulter Electronics, Inc., Hialeah, FL). Each well contained 2x 10^4cells in a total volume of 200 μL. The plate included blank wells (0 cells/mL), control wells (2 x10^4cells/0.2 Ml, untreated group), control wells with DMSO (no cells), control wells treated with SR140333 (Nolpitantium) (10^-9M-10^-5M), control wells treated with SMSP (10^-10M-10^-6M) and control wells treated with SMSP (most effective concentration) combined with different concentrations of SR140333 (10^-9M-10^-5M). Drugs were added on day 3 (at exponential phase) and the assay was performed after 24 hours. For the proliferation assay, 20 μL MTT was added to each well. After 4 hours at 37°C supernatant was removed and 100 μL DMSO was added to each well. The optical density (OD) was detected in the microplate reader at 570 nm wavelength
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C267
Created by
admin on Fri Dec 15 17:05:27 GMT 2023 , Edited by admin on Fri Dec 15 17:05:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1178725
Created by
admin on Fri Dec 15 17:05:27 GMT 2023 , Edited by admin on Fri Dec 15 17:05:27 GMT 2023
|
PRIMARY | |||
|
3047794
Created by
admin on Fri Dec 15 17:05:27 GMT 2023 , Edited by admin on Fri Dec 15 17:05:27 GMT 2023
|
PRIMARY | |||
|
C97964
Created by
admin on Fri Dec 15 17:05:27 GMT 2023 , Edited by admin on Fri Dec 15 17:05:27 GMT 2023
|
PRIMARY | |||
|
SUB09344MIG
Created by
admin on Fri Dec 15 17:05:27 GMT 2023 , Edited by admin on Fri Dec 15 17:05:27 GMT 2023
|
PRIMARY | |||
|
DTXSID70165897
Created by
admin on Fri Dec 15 17:05:27 GMT 2023 , Edited by admin on Fri Dec 15 17:05:27 GMT 2023
|
PRIMARY | |||
|
100000083586
Created by
admin on Fri Dec 15 17:05:27 GMT 2023 , Edited by admin on Fri Dec 15 17:05:27 GMT 2023
|
PRIMARY | |||
|
7486
Created by
admin on Fri Dec 15 17:05:27 GMT 2023 , Edited by admin on Fri Dec 15 17:05:27 GMT 2023
|
PRIMARY | |||
|
SN2G80PK4I
Created by
admin on Fri Dec 15 17:05:27 GMT 2023 , Edited by admin on Fri Dec 15 17:05:27 GMT 2023
|
PRIMARY | |||
|
155418-06-7
Created by
admin on Fri Dec 15 17:05:27 GMT 2023 , Edited by admin on Fri Dec 15 17:05:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD